New Delhi, May 26, 2025: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for Q4FY25 ended March 31, 2025.
Q4FY25 Results:
- For the fourth quarter of FY 2024-25, Glenmark’s consolidated revenue was at Rs. 32,562 Mn as against Rs. 30,630 Mn recording an increase of 6.3% YoY.
- EBITDA was Rs. 5,607 Mn in the quarter ended March 31, 2025, as compared to Rs. 5,043 Mn in the previous corresponding quarter, registering growth of 11.2%. EBITDA margin for the quarter was 17.2%.
- Adjusted Profit After Tax (PAT)# for the quarter ended March 31, 2025 was at Rs. 3,466 Mn with adjusted PAT margin# of 10.6%.
FY25 Results:
- For the year ended March 31, 2025, Glenmark’s consolidated revenue was at Rs. 1,33,217 Mn as against Rs. 1,18,131 Mn, recording an increase of 12.8% over the previous corresponding period.
- EBITDA for the fiscal year ended March 31, 2025 stood at Rs. 23,510 Mn as against Rs. 11,953 Mn in the previous corresponding period. EBITDA margin for FY 2024-25 was at 17.6%.
- Adjusted Profit After Tax (PAT)# for the year ended March 31, 2025 was at Rs. 13,894 Mn, with adjusted PAT margin# of 10.4%.
Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, “Our performance reflects the underlying resilience of our business, the strength of our diversified portfolio, and the focused execution of our strategic priorities. The Europe business has shown strong growth, and our branded businesses have delivered sustained results, supported by market expansion and a sharp therapeutic focus. As we move into FY26, we remain committed to building this momentum as we strengthen our global footprint.
We are also proud to share that our innovation-led pipeline continues to gain momentum, with Ichnos Glenmark Innovation (IGI) receiving US FDA Fast Track designation for ISB 2001 — a significant milestone in our journey towards advancing cutting-edge biologics for cancer care. This recognition marks a critical step forward in our aspiration to bring transformative therapies to patients and reinforces our commitment to being a science-led, future-ready organization.”
